Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures

This study is using genetic analysis of tumor tissue (called transcriptomic profiling) to personalize which chemotherapy regimen is most likely to work for each patient with advanced pancreatic cancer, instead of using the same treatment for everyone. **You may be eligible if...** - You have been diagnosed with advanced (metastatic) pancreatic ductal adenocarcinoma — the most common type of pancreatic cancer - You have not yet received chemotherapy for your advanced cancer - You are 18 or older in good overall health (ECOG 0–1) - Tumor tissue is available for genetic testing **You may NOT be eligible if...** - You have previously received chemotherapy for metastatic disease (prior adjuvant/neoadjuvant chemotherapy is not allowed) - You have severe organ dysfunction (liver, kidneys, bone marrow) - You have a specific enzyme deficiency (DPD deficiency) that makes certain chemotherapy drugs dangerous - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.